Journal of neuroendocrinology · 2025
Endoscopic submucosal dissection for gastric neuroendocrine neoplasms: A multicenter retrospective study.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lazaridis Nikolaos, Rimondi Alessandro, Chacchi-Cahuin Rocio, Lemmers Arnaud, Costa Deborah, Bucalau Ana-Maria, Mandair Dalvinder, Gupta Sunil, Tantau Marcel, Pioche Mathieu, Rivory Jérôme, Santos-Antunes João, Marques Margarida, Ramos Zabala Felipe, Barbaro Federico, Pimentel-Nunes Pedro, Uchima Hugo, Albeniz Eduardo, Dinis-Ribeiro Mario, Costamagna Guido, Spada Cristiano, Bourke Michael, Caplin Martyn, Toumpanakis Christos, Despott Edward J, Murino Alberto
Аннотация
Endoscopic submucosal dissection (ESD) has been reported as a feasible and effective treatment for Gastric Neuroendocrine Tumors (G-NETs). However, most of the experience comes from retrospective tertiary centers in Eastern Asia. Data coming from western centers are lacking. This is a retrospective study, including patients who underwent endoscopic resection of G-NETs by ESD between 2010 and 2020 in Western Centers. Important clinical variables such as demographic, size, type, presence of lymphovascular invasion or distant metastasis, completeness of the endoscopic resection, recurrence, and procedure-related complications were recorded. Seventy-three ESD procedures on G-NETs from 69 patients from 11 centers were included. Median G-NETs size on endoscopy was 12 mm (IQR 10-15). Case mix accounted for 83.6% type 1, 15.1% type 3, and 1.4% type 2. En-bloc resection was possible in 69 procedure 94.5%, R0 resection rate stood at 79.5%. Five patients (7.2%) were referred for additional surgical intervention. One case of perforation was reported (1.4%), treated endoscopically. Three patients (4.4%) had evidence of recurrence during follow-up. ESD is an effective and safe treatment for G-NETs in western centers.